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In late 2019, a mass of patients showing 
symptoms of a pneumonia-like disease of 
unknown origin emerged in Wuhan, China. 
Little did the world know it was the prelude 
of what would be a devastating pandemic. 
Samples were collected from these patients and 
the use of unbiased sequencing and subsequent 
isolation of the pathogen using human airway 
epithelial cells led to the discovery of a novel 
coronavirus, named 2019-nCoV by the World 
Health Organization (WHO) and Severe Acute 
Respiratory Syndrome CoronaVirus-2 (SARS-
CoV-2) by the International Committee on 
Taxonomy of Viruses.1,2 The disease caused by 
this virus is officially called the coronavirus 
disease 2019 (COVID-19).
Coronaviruses are enveloped RNA viruses 
that are spherical in shape with bulbous surface 
projections.1,3 Currently, there are six known 
species of coronavirus that can cause various 
systemic diseases in humans.1 Two of the 
six species of coronaviruses – Severe Acute 
Respiratory Syndrome Coronavirus (SARS-
CoV) and the Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV) – originated from 
animals and have caused outbreaks in the past 
with relatively high mortality rates.4 SARS-CoV 
and MERS-CoV have been shown to possess the 
potential to cause severe and potentially fatal 
respiratory tract infections.5
SARS-CoV-2 is a highly transmissible 
beta-coronavirus that could infect humans by 
binding into the angiotensin-converting enzyme 
2 (ACE2) receptor, the same receptor as SARS-
CoV.5 The genome sequence of SARS-CoV-2 
has been found to share 79.5% identity to 
SARS-CoV and is 96.2% identical to a strain of 
bat CoV, raising the suspicion that bats may be 
the natural host and reservoir of SARS-CoV-2.5 
Pangolin is the most likely intermediate host of 
SARS-CoV-2 between bats and humans, based 
on preliminary data.2
From the discovery of SARS-CoV-2 in late 
2019 until January 24, 2020, there had been 830 
confirmed cases of COVID-19 in nine countries 
with 26 fatalities.6 Since then, the virus has been 
spreading aggressively on a global scale, and 
the number of cases has grown exponentially. 
By March 12, 2020, 116 countries had been 
affected, and 118,000 confirmed cases had been 
reported.7 In March 28, 2020, the Johns Hopkins 
Coronavirus Research Center database had 
confirmed a total of 615,519 cases of COVID-19 
in 177 countries with 28,717 fatalities.
COVID-19 primarily manifests as an 
acute respiratory infectious disease, as shown 
by the clinical findings several recent studies 
have found. Generally, the most common 
symptoms found in COVID-19 patients include 
fever, dry cough, fatigue, expectoration, and 
malaise, with gastrointestinal symptoms such as 
diarrhea occurring infrequently or sporadically 
throughout the illness.8-10 Though not yet well-
documented, Li et al.11 have suggested that ocular 
manifestations such as unilateral or bilateral 
conjunctivitis are still a possibility in COVID-19, 
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based on a previous report in Wuhan, where a 
healthcare worker donning full protective gear 
except goggles was infected, with unilateral 
conjunctivitis preceding the onset of illness. 
The spectrum of disease severity in COVID-19 
varies from asymptomatic, mild, moderate, to 
severe and critical. In severe cases, COVID-19 
patients could develop acute respiratory distress 
syndrome (ARDS), respiratory failure, sepsis, 
multiple organ failure, and death.5,10 ARDS 
commonly develops on day 8 to 12 from the 
onset of illness.9,10
Recent studies have reported that white 
blood cell (WBC) count tends to be normal in 
most patients, though some experience a minor 
decrease in WBC.5,10 Decreased total lymphocyte 
or lymphocytopenia is a common occurrence.8,9 
Increased coagulation activity marked by elevated 
d-dimer concentrations were also common, but 
significant elevation of greater than 1 mcg/ml is 
associated with poor prognosis.8,10,12 Generally, 
marked alteration of coagulation parameters 
increase the risk of disseminated intravascular 
coagulation (DIC) and could subsequently lead 
to a poor patient outcome that results in death. 
Procalcitonin is an inflammatory marker that is 
not usually substantially increased in COVID-19 
patients, and a gradual increase in concentration 
could indicate a bacterial superinfection or a 
superimposed bacterial infection.13 However, 
another inflammatory marker, C-reactive protein 
(CRP), has generally been shown to increase and 
is directly proportional to disease severity and 
poor prognosis.14,15 Other laboratory predictors 
of poor outcome include a higher sequential 
organ failure assessment (SOFA) score, which 
encompasses the respiratory (PaO2/FIO2), 
coagulation (platelets), cardiovascular (mean 
arterial pressure), hepatic (bilirubin), neurological 
(Glasgow comma scale), and renal (creatinine) 
systems, increased lactate dehydrogenase, and 
increased cardiac troponin.10,13
As of March 2, 2020, the WHO’s interim 
guidance on laboratory testing for COVID-19 still 
recommends the use of nucleic acid amplification 
tests (NAAT), such as reverse-transcriptase 
polymerase chain reaction (RT-PCR), to screen 
suspect cases.16 The specimens recommended 
to be collected are upper respiratory materials 
(nasopharyngeal and oropharyngeal swab) 
and/or lower respiratory materials (sputum/
endotracheal aspirate/bronchoalveolar lavage).16 
However,  recent radiological studies concerning 
the remarkable sensitivity of chest computed 
tomography (CT) scan in diagnosing COVID-19 
patients raises the question on whether or 
not chest CT should be a  staple modality in 
diagnosing COVID-19.17,18 Studies by Fang et 
al.17 and Ai et al.18 have found the sensitivity of 
chest CT in diagnosing COVID-19 to be 98% 
and 97% respectively. Subsequently, a subgroup 
of patients in the study of Ai et al.18 showed 
positive chest CT scans prior or within 6 days 
of the initial positive RT-PCR results. Chest CT 
has even been shown to be a reliable screening 
tool in asymptomatic patients, as shown by the 
study of Shi et al.19, substantiating the suggestion 
that asymptomatic patients could develop 
abnormalities in chest CT prior to the onset of 
symptoms. Patients with NCP generally show 
signs of bilateral subpleural ground-glass opacity, 
consolidation, and sometimes accompanied by 
the thickening of the interlobular septum often 
called a “crazy paving stone-like” pattern.19,20 
Several other studies also support the notion of 
using chest CT as a screening tool in subjects 
with negative RT-PCR results suspected with 
COVID-19 infection based on their exposure 
history and/or clinical symptoms.17,18 RT-PCR 
is still a reliable diagnostic tool, although 
there are some factors that may compromise 
the efficiency. Those factors include improper 
sampling technique, varying detection rate 
due to different manufacturers, low viral load, 
and imperfect development of nucleic acid 
detection technology.17 Overall, in the context 
of a rapidly needed emergency disease control 
like COVID-19, physicians should adjust and 
utilize their arsenal of diagnostic tools to find 
the balance between swiftness and accuracy, and 
chest CT might help to find that balance.
Another radiological modality as a possible 
screening or diagnostic tool for COVID-19 is 
the lung ultrasound (LUS). In LUS, COVID-19 
is characterized by a patchy distribution of 
subpleural consolidation with associated areas 
of white lung.21 LUS may be useful in healthcare 
facilities that may not have sophisticated 
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radiological or laboratory equipment necessary 
to diagnose COVID-19, as ultrasound devices 
are commonly more readily available than CT 
and RT-PCR test kits, especially in primary 
and secondary healthcare facilities. LUS may 
be useful in the emergency room setting and in 
monitoring disease progression in ICU patients 
using a ventilator, as the mobility of these 
patients are usually very limited and performing 
radiological examinations such as CT scan would 
be extremely difficult. LUS is also safer in terms 
of radiation exposure compared to CT and should 
be considered as a viable option in children 
suspected with COVID-19. Nonetheless, it 
should be noted that LUS is heavily dependent 
on a skilled operator, and different operators 
might have different interpretations based on 
their subjectivity. LUS operators should also 
be equipped with proper personal protective 
equipment (PPE) as they are in close proximity 
with suspected patients while conducting 
examinations.
Recently, the United States (US) Food 
and Drug Administration (FDA) has given an 
emergency use authorization (EUA) to Abbott 
Laboratories for the use of their product called 
the Abbott ID NOW COVID-19 test that runs on 
Abbott’s ID NOW™ platform. This lightweight 
and portable assay device is claimed to be “fastest 
available molecular point-of-care test for novel 
coronavirus”, and can deliver positive results in 
a mere five minutes and negative results in 13 
minutes by targeting the RdRP Gene of the virus. 
If this claim is substantiated and could perform 
with high sensitivity and specificity, this product 
could significantly help healthcare workers in 
diagnosing COVID-19, which subsequently 
would enhance response time for management 
and isolation, and overall help lessens the 
spread of COVID-19. Abbott Laboratories is 
expected to produce around 5 million tests in 
April, and deliver another 50,000 tests per day. If 
successful, the use of this rapid immunoassay test 
in the US could serve as a precedent for screening 
programs in other countries, including Indonesia.
Given these are what we currently 
comprehend about COVID-19, it is imperative 
for each physician on the frontlines to equip 
themselves with the latest diagnostic proficiency 
in order to tackle this challenge in an efficient 
manner. As different physicians in different 
healthcare facilities face different circumstances, 
the use of adaptive and structured diagnostic 
method is essential in identifying the most 
appropriate management strategy, preventing 
poor prognosis and outcome, and overall help 
reduces the spread of COVID-19.
Another issue worth addressing that could 
supplement efficient diagnosis in facing this 
challenge includes infrastructural improvements 
such as the establishment of an accessible real-
time and transparent ICU information network 
between healthcare facilities where laboratory 
and radiological results could be accessed 
securely, and the establishment of adequate 
numbers of contemporary laboratories that could 
efficiently run RT-PCR tests in a designated 
region. Qualified healthcare workers should 
also be distributed evenly with sustainable 
working hours and sufficient equipment to 
ensure patient safety and their well-being. 
Understandably, addressing these issues will 
require sophisticated planning and execution will 
not be straightforward, but problem identification 
is always the first step in resolving any challenge.
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